Latest Breaking News On - Immune tolerance breaking technology - Page 1 : comparemela.com

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities.

United statesLos angelesProduct development centerPrnewswire transcenta holding limitedTranscenta immune tolerance breaking technologyClinical development centers in princetonGroup headquartersTranslational research centerHolding limitedClinical oncology volumeImmune tolerance breaking technologyOrphan drug designationManufacturing facilityClinical development centersExternal partnering centerSuzhou industrial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18 2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18 2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul beresfordCaroline germaLos angelesProduct development centerClinical development centersTranscenta holdingTranscenta immune tolerance breaking technologyGlobal medicine developmentPrnewswire transcenta holding limitedTranslational research centerGroup headquartersAgilent technologiesHolding limitedInvestigational usePerformance evaluation only

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

United statesCaroline germaLos angelesTranscenta holdingTranscenta immune tolerance breaking technologyTranscenta holding limitedClinical development centers in princetonTranslational research centerProduct development centerGlobal medicine developmentGroup headquartersExecutive vice presidentChief medicalManageable safetyImmune tolerance breaking technologyOrphan drug designation

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in.

South koreaUnited statesLos angelesCaroline germaProduct development centerTranscenta holdingPrnewswire transcenta holding limitedBusiness development centerClinical development centers in princetonGroup headquartersGlobal medicine developmentTranslational research centerTranscenta immune tolerance breaking technologyGlobal therapyCurrent standardHolding limited

Transcenta to Present Three Study Results at ESMO 2023

Transcenta to Present Three Study Results at ESMO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLin shenXueming qianLos angelesProduct development centerPrnewswire transcenta holding limitedTranslational research centerGroup headquartersBusiness development centerClinical development centersTranscenta holdingTranscenta immune tolerance breaking technologyEuropean society of medical oncologySuzhou transcenta therapeutics co ltdHolding limitedMedical oncology